Expression of HPV16 E6 recombinant protein and preparation of its rabbit polyclonal antibody

0 Comments
medicalpeek

Era of Excessive Affinity Anti-Peptide Polyclonal Antibodies Recognizing Goat α s1-Casein

 

The chemical, technological and allergy properties of goat’s milk are considerably affected by the extent of αs1-casein. Detection and quantification of αs1-casein requires high-specificity strategies to beat high-sequence similarity between this protein and others within the casein household. Unavailability of antibodies with excessive affinity and specificity in direction of goat αs1-casein hinders the event of immuno-based analytical strategies corresponding to enzyme-linked immunosorbent assay (ELISA) and biosensors.

Right here, we report the era of polyclonal antibodies (or immunoglobulins, IgGs) raised in direction of goat αs1-casein N- (Nter) and C-terminal (Cter) peptide sequences. The Nter and Cter peptides of goat αs1-casein have been immunized in rabbits for the era of antisera, which have been purified utilizing protein G affinity chromatography. The binding affinity of the antisera and purified IgGs have been examined and in contrast utilizing oblique ELISA, the place peptide-BSA conjugates and goat αs1-casein have been used because the coating antigens.

The Nter antiserum displayed greater titer than Cter antiserum, at 1/64,000 and 1/32,000 dilutions, respectively. The purification step additional yielded 0.5 mg/mL of purified IgGs from Three mL of antisera. The purified Nter IgG confirmed a considerably (p < 0.05) greater binding affinity in direction of peptide-BSA and goat αs1-casein, with decrease Okd worth at 5.063 × 10-3 μM in comparison with 9.046 × 10-3 μM for the Cter IgG. A cross-reactivity check confirmed that there was no binding in neither Nter nor Cter IgGs in direction of protein extracts from the milk of cow, buffalo, horse and camel. Excessive-quality antibodies generated will permit additional improvement of immuno-based analytical strategies and future in vitro research to be performed on goat αs1-casein.

Expression of HPV16 E6 recombinant protein and preparation of its rabbit polyclonal antibody

 

Goal To specific E6 protein of human papillomavirus (HPV) kind 16 in prokaryotic expression system and put together its polyclonal antibody. Strategies HPV16 E6 gene was obtained from Siha cells by PCR and cloned into pET21a(+) vector to assemble the recombinant plasmid pET21a(+)/HPV16 E6 that was confirmed by sequencing. The recombinant plasmid pET21a(+)/HPV16 E6 was remodeled into E. coli BL21 (DE3).

The HPV16 E6-His tag recombinant protein was expressed after the induction of isopropyl beta-D-1-thiogalactopyranoside (IPTG), purified by Ni-NTA affinity chromatography, after which analyzed by Western blot evaluation. The purified HPV16 E6 recombinant protein was used to immunize Japanese white rabbits to organize polyclonal antibody. The titer of the serum polyclonal antibody was decided by ELISA. The specificity of the polyclonal antibody was analyzed by Western blotting and immunofluorescence.

Outcomes The recombinant plasmid pET21a(+)/HPV16 E6 was efficiently constructed and confirmed by sequencing. After the recombinant plasmid pET21a(+)/HPV16 E6 was remodeled into E. coli BL21 (DE3), the recombinant HPV16 E6 protein was expressed and purified by affinity chromatography.

The polyclonal antibody at a titer of 1:40 000 was obtained by immunizing Japanese big-ear white rabbit with the purified recombinant HPV16 E6 protein, and its specificity was confirmed by Western blotting and immunofluorescence assay. Conclusion HPV16 E6 recombinant protein was efficiently expressed and the rabbit polyclonal antibody in opposition to HPV16 E6 recombinant protein was ready.

Manufacturing of polyclonal antibody in opposition to kidney antigens: a mannequin for finding out autoantibody in feline continual kidney illnesses.

 

  • Continual kidney illness is taken into account to be most typical in geriatric home cats. It has been reported that the feline viral rhinotracheitis, calicivirus, and panleukopenia (FVRCP) vaccine ready from the Crandell-Rees feline kidney (CRFK) cell line can induce cross-reactions of antibodies with feline kidney tissues.
  • As an anti-cat kidney antibody was not accessible commercially for this examine of autoantibody in cats, the aim of this examine was to provide anti-cat kidney antibody in rabbits for additional examine of autoantibody in cats after FVRCP vaccination.

 

  • Kidney proteins from cadaveric cats have been extracted and immunized into rabbits utilizing Montanide because the adjuvant. Based mostly on enzyme-linked immunosorbent assay measurement, all immunized rabbits produced excessive ranges of anti-cat kidney antibodies and a few started to provide antibodies as early as 2 weeks after immunization. Immunofluorescence staining of rabbit sera confirmed kidney-bound antibodies in glomerulus, Bowman’s capsule, apical floor of the proximal convoluted tubule, peritubular floor, and interstitial cells.

 

  • Western blot evaluation of cat kidney proteins revealed molecular weights (M.W.) of 72, 55, 47, and 31 kDa, whereas binding to the CRFK cell proteins was noticed at M.W. of 43 and 26 kDa. The antibody that acknowledged the 47 kDa protein was equally detected in cats with autoantibody presence after FVRCP vaccination. The kidney-bound antibody profile at totally different time factors and its patterns in rabbits may very well be used as a mannequin for the examine of autoantibody to cat kidney in feline continual kidney illnesses.
medicalpeek
medicalpeek

gel casting base for evs3100

EVS3100-BASE ea
EUR 361.2

gel casting base for evs3200

EVS3200-BASE ea
EUR 361.2

gel casting base for evs3300

EVS3300-BASE ea
EUR 361.2

Vatalanib, Free Base

2026-25
EUR 366

Vatalanib, Free Base

2026-5
EUR 151.2

Erlotinib, Free Base

2048-100
EUR 189.6

Erlotinib, Free Base

2048-1000
EUR 464.4

Sunitinib, Free base

2097-100
EUR 229.2

Sunitinib, Free base

2097-1000
EUR 601.2

Sunitinib, Free base

2097-25
EUR 138

Ruxolitinib (free base)

10-042 25 mg
EUR 418.2
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19).

Lapatinib, Free base

2138-100
EUR 464.4

Lapatinib, Free base

2138-25
EUR 229.2

Ruxolitinib, Free base

2139-100 Ask for price

Ruxolitinib, Free base

2139-25
EUR 639.6

Ruxolitinib, Free base

2139-5
EUR 248.4

Imatinib, Free base

2141-100
EUR 176.4

Imatinib, Free base

2141-1000
EUR 502.8

Linsitinib, Free base

2294-25
EUR 679.2

Linsitinib, Free base

2294-5
EUR 222

Tipifarnib, Free base

2296-1
EUR 170.4

Tipifarnib, Free base

2296-5
EUR 496.8

Rucaparib (free base)

A8893-10 10 mg
EUR 240
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-200 200 mg
EUR 1243.2
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5 5 mg
EUR 164.4
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5.1 10 mM (in 1mL DMSO)
EUR 170.4
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-50 50 mg
EUR 547.2
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

LY2835219 free base

A3575-100 100 mg
EUR 686.4
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-25 25 mg
EUR 309.6
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-5 5 mg
EUR 170.4
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

R406 (free base)

A5880-100 100 mg
EUR 1452
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-25 25 mg
EUR 616.8
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-5 5 mg
EUR 199.2
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-5.1 10 mM (in 1mL DMSO)
EUR 316.8
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-S Evaluation Sample
EUR 97.2
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

THZ1 (Free base)

9664-25
EUR 1227.6

THZ1 (Free base)

9664-5
EUR 352.8

MCC950 (Free base)

B1031-1
EUR 183.6

MCC950 (Free base)

B1031-5
EUR 548.4

FIPI (free base)

B2372-25
EUR 757.2

FIPI (free base)

B2372-5
EUR 235.2

Terbinafine (Free base)

B2423-250
EUR 248.4

Terbinafine (Free base)

B2423-50
EUR 144

PLX5622 (free base)

B2965-25 25 mg
EUR 903.6

PLX5622 (free base)

B2965-5 5 mg
EUR 272.4

Apatinib (Free base)

B1613-25
EUR 496.8

Apatinib (Free base)

B1613-5
EUR 170.4

Carubicin (Free base)

B1853-1
EUR 183.6

Carubicin (Free base)

B1853-5
EUR 548.4

AZD4547, Free Base

ADC-P-063 unit Ask for price

AZD8055, Free Base

ADC-P-064 unit Ask for price

Cyclopamine, Free Base

ADC-P-079 unit Ask for price

Ixabepilone, Free Base

ADC-P-104 unit Ask for price

R406(free base)

E1KS1533 2mg
EUR 625.2

Ripasudil free base

HY-15685A 10mg
EUR 489.6

Vatalanib (free base)

HY-10203 5mg
EUR 142.8

RPR107393 free base

HY-100299 1mg
EUR 577.2

FR167344 free base

HY-100301 1mg
EUR 3164.4

FR183998 free base

HY-100302 1mg
EUR 1352.4

FR194738 free base

HY-100303 1mg
EUR 2388

YM158 (free base)

HY-U00355 1mg
EUR 2770.8

Masupirdine (free base)

HY-109118 1mg
EUR 267.6

R406 (free base)

HY-11108 10mM/1mL
EUR 277.2

ITI214 (free base)

HY-12501 100mg
EUR 3531.6

AS2863619 (free base)

HY-126675 5mg
EUR 1410

AZD3839 (free base)

HY-13438 50mg
EUR 1216.8

TMB free base

TB0954 1g
EUR 85.06

Xylazine (free base)

Q-1445.0025 25.0g
EUR 385.2
Description: Sum Formula: C12H16N2S; CAS# [7361-61-7]

Afatinib

A170-100MG 100mg
EUR 122.4

Afatinib

HY-10261 200mg
EUR 374.4

RGB-286638,  free base

2886-25
EUR 907.2

RGB-286638,  free base

2886-5
EUR 274.8

GSK-J4 (Free base)

2762-1
EUR 144

GSK-J4 (Free base)

2762-5
EUR 314.4

StemRegenin 1, Free base

2642-1
EUR 157.2

StemRegenin 1, Free base

2642-5
EUR 398.4

AM-095 free base

A3167-10 10 mg
EUR 254.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-100 100 mg
EUR 964.8
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-200 200 mg
EUR 1382.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-5 5 mg
EUR 199.2
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-50 50 mg
EUR 686.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

SGI-1776 free base

A4192-10 10 mg
EUR 296.4
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-5 5 mg
EUR 184.8
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-5.1 10 mM (in 1mL DMSO)
EUR 199.2
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-50 50 mg
EUR 630
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-S Evaluation Sample
EUR 97.2
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

L-Arginine free base

AB0205 100g
EUR 75.78

GSK J4 free base

B5959-10 10 mg
EUR 447.6
Description: GSK J4 free base

GSK J4 free base

B5959-50 50 mg
EUR 1437.6
Description: GSK J4 free base

Staurosporine, >99% Free Base

BC090-001 1mg
EUR 295.2

Staurosporine, >99% Free Base

BC090-005 5mg
EUR 408

Vandetanib, >99% Free Base

BC098-025 25mg
EUR 278.4

Vandetanib, >99% Free Base

BC098-050 50mg
EUR 343.2

Vandetanib, >99% Free Base

BC098-100 100mg
EUR 375.6

Vandetanib, >100% Free Base

BC098-500 500mg
EUR 789.6

UNC-926, free base

B2158-25
EUR 757.2

UNC-926, free base

B2158-5
EUR 235.2

SB-334867 free base

B3423-100 100 mg
EUR 718.8
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-25 25 mg
EUR 348
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-5 5 mg
EUR 153.6
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-5.1 10 mM (in 1mL DMSO)
EUR 157.2
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

BMS-345541(free base)

B4655-10 10 mg
EUR 282
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541(free base)

B4655-5 5 mg
EUR 205.2
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541(free base)

B4655-50 50 mg
EUR 714
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541 (Free base)

B1907-1
EUR 170.4

BMS-345541 (Free base)

B1907-5
EUR 496.8

JTV-519 (free base)

HY-15293A 5mg
EUR 680.4

RGB-286638 (free base)

HY-15504A 100mg
EUR 3364.8

DOV-216,303 (Free Base)

HY-18332C 10mM/1mL
EUR 590.4

FK-448 Free base

HY-100193 10mg
EUR 2264.4

KW-8232 free base

HY-100304 10mg
EUR 6021.6

YM-53601 free base

HY-100313 1mg
EUR 1870.8

CP-319340(free base)

HY-U00270 5mg
EUR 1052.4

AV-412 (free base)

HY-10346A 5mg
EUR 207.6

SB-334867 (free base)

HY-10895A 10mg
EUR 258

SNT-207858 (free base)

HY-11030A 10mg
EUR 1093.2

APX-115 (free base)

HY-120801A 5mg
EUR 267.6

LY-2584702 (free base)

HY-12493 5mg
EUR 198

Genz-123346 (free base)

HY-12744 10mM/1mL
EUR 226.8

YHO-13351 (free base)

HY-12758A 10mM/1mL
EUR 211.2

Z-NHNH2 (free base)

Q-1150.0025 25.0g
EUR 151.2
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

Z-NHNH2 (free base)

Q-1150.0100 100.0g
EUR 385.2
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

Afatinib dimaleate

A3145-10 10 mg
EUR 265.2
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-5 5 mg
EUR 176.4
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-5.1 10 mM (in 1mL DMSO)
EUR 142.8
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-50 50 mg
EUR 614.4
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib (BIBW2992)

A8247-10 10 mg
EUR 265.2
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-5 5 mg
EUR 176.4
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-5.1 10 mM (in 1mL DMSO)
EUR 292.8
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-50 50 mg
EUR 614.4
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-S Evaluation Sample
EUR 97.2
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (dimaleate)

HY-10261A 200mg
EUR 374.4

Human Free PSA (f-PSA) ELISA Kit

PRB-5049-FREE 96 assays
EUR 686.4

BAY 43-9006, Free base

2142-100
EUR 502.8

BAY 43-9006, Free base

2142-25
EUR 202.8

BAY 58-2667 (Free base)

2452-1
EUR 424.8

BAY 58-2667 (Free base)

2452-5
EUR 1358.4

EZSolution? StemRegenin 1, Free base

2643-1
EUR 170.4

Biotin ethylenediamine (free base form)

90071 25MG
EUR 158.4
Description: Minimum order quantity: 1 unit of 25MG

biotin cadaverine, free base form

90079 50MG
EUR 258
Description: Minimum order quantity: 1 unit of 50MG

SB 202190, >99% Free Base

BC086-025 25mg
EUR 246

SB 202190, >99% Free Base

BC086-050 50mg
EUR 295.2

SB 203580, >99% Free Base

BC087-025 25mg
EUR 262.8

SB 203580, >99% Free Base

BC087-050 50mg
EUR 343.2

H-Tyr-OEt (free base)

E-2900.0025 25.0g
EUR 166.8
Description: Sum Formula: C11H15NO3; CAS# [949-67-7]

H-Tyr-OEt (free base)

E-2900.0100 100.0g
EUR 428.4
Description: Sum Formula: C11H15NO3; CAS# [949-67-7]

Glyoxalase I inhibitor (free base)

HY-15167A 50mg
EUR 3036

Bay 65-1942 (free base)

HY-50949 10mg
EUR 1282.8

Gastrofensin AN 5 free base

HY-100296 5mg
EUR 2544

biotin-x cadaverine, free base form

90080 20MG
EUR 258
Description: Minimum order quantity: 1 unit of 20MG

H-Arg(Mtr)-OtBu (free base)

E-3075.0001 1.0g
EUR 370.8
Description: Sum Formula: C20H34N4O5S; CAS# [115608-61-2]

H-Arg(Mtr)-OtBu (free base)

E-3075.0005 5.0g
EUR 1371.6
Description: Sum Formula: C20H34N4O5S; CAS# [115608-61-2]

H-Arg(Pmc)-OtBu (free base)

E-3085.0001 1.0g
EUR 501.6
Description: Sum Formula: C24H40N4O5S; CAS# [169543-81-1]

H-Arg(Pmc)-OtBu (free base)

E-3085.0005 5.0g
EUR 1864.8
Description: Sum Formula: C24H40N4O5S; CAS# [169543-81-1]

Cyclosporin A-Derivative 1 (Free base)

HY-P1355A 1mg
EUR 267.6

PNU-282987 (S enantiomer free base)

HY-12560D 5mg
EUR 1216.8

Human Free PSA (f-PSA) ELISA Kit

PRB-5049-FREE-5 5 x 96 assays
EUR 2739.6

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-002 2 mg
EUR 213.6

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-005 5 mg
EUR 318

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-010 10 mg
EUR 378

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-025 25 mg
EUR 472.8

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-100 100 mg
EUR 1064.4

H-Ala-Ala-Phe-AMC (free base)

I-1415.0050 50.0mg
EUR 181.2
Description: Sum Formula: C25H28N4O5; CAS# [62037-41-6]

H-Ala-Ala-Phe-AMC (free base)

I-1415.0250 250.0mg
EUR 618
Description: Sum Formula: C25H28N4O5; CAS# [62037-41-6]

(D-Ser(tBu)6,Azagly10)-LHRH (free base)

H-7296.0005 5.0mg
EUR 219.6
Description: Sum Formula: C59H84N18O14; CAS# [65807-02-5]

(D-Ser(tBu)6,Azagly10)-LHRH (free base)

H-7296.0025 25.0mg
EUR 769.2
Description: Sum Formula: C59H84N18O14; CAS# [65807-02-5]

Tris-base

20-abx082498
  • EUR 393.60
  • EUR 243.60
  • EUR 493.20
  • 1 kg
  • 500 g
  • 5 kg

casting base

EHS3100-CAST ea
EUR 128.4

casting base

EHS3200-CAST ea
EUR 148.8

casting base

EHS3300-CAST ea
EUR 148.8

Tetracycline base

GA9779-100G 100 g
EUR 180

Tetracycline base

GA9779-10G 10 g
EUR 55.2

Tetracycline base

GA9779-25G 25 g
EUR 74.4

Rimonabant base

GX9120-10MG 10 mg
EUR 103.2

Rimonabant base

GX9120-25MG 25 mg
EUR 156

ProteoIQ Base

PS2 1
EUR 5114.4

Vincamine base

Q-1435.0005 5.0g
EUR 270
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9]

Vincamine base

Q-1435.0025 25.0g
EUR 963.6
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9]

Channel Base

C653 EACH
EUR 22.46

Positioning Base

S44I041002 EACH
EUR 1409.04

CETRIMIDE AGAR BASE

C03-107-10kg 10 kg
EUR 1474.8

CETRIMIDE AGAR BASE

C03-107-2Kg 2 Kg
EUR 367.2

CETRIMIDE AGAR BASE

C03-107-500g 500 g
EUR 144

MYCOPLASMA BROTH BASE

M13-136-10kg 10 kg
EUR 2108.4

MYCOPLASMA BROTH BASE

M13-136-2kg 2kg
EUR 505.2

MYCOPLASMA BROTH BASE

M13-136-500g 500 g
EUR 181.2

Preparation and software of mouse polyclonal antibodies in opposition to human Shisa like 1 (SSL1)

 

Goal: To organize polyclonal antibodies in opposition to Shisa like 1 protein (SSL1) and examine the localization of SSL1 in hepatocellular carcinoma SMMC-7721 cells.

Strategies: Human SSL1 gene was cloned from HepG2 cells by reverse transcription PCR, after which inserted into prokaryotic expression vector pET-28a to generate the SSL1 expression vector. The recombinant plasmid pET28a-SSL1 was then remodeled into E. coli BL21 (DE3) and induced to specific by IPTG.

Polyclonal antibody in opposition to SSL1 was generated by immunizing Kunming mouse with the purified protein by the routine methodology. The specificity of polyclonal antibody was verified by Western blot evaluation. The expression of SSL1 in SMMC-7721 cells was detected by immunofluorescent cytochemistry. Golgi complexes have been signed by Golgi-Tracker Purple to investigate the subcellular localization of SSL1 protein in SMMC-7721 cells.

 

Outcomes The SSL1 gene was cloned and the recombinant vector pET28a-SSL1 was efficiently constructed. Pure SSL1 protein expression in E. coli BL21 was confirmed and polyclonal antibodies in opposition to protein SSL1 was obtained in immunized Kunming mice. Immunofluorescent cytochemistry confirmed that SSL1 was expressed within the cytoplasm, and was co-localized with Golgi-Tracker Purple in SMMC-7721 cells. Conclusion We’ve obtained SSL1 polyclonal antibodies with excessive specificity, which was proved located in Golgi our bodies of SMMC-7721 cells.

 

Improvement and characterization of polyclonal antibody in opposition to human kappa gentle chain in rabbit.

 

Polyclonal antibodies in opposition to kappa gentle chain are used to diagnose illnesses producing free gentle chain. The kappa and lambda gentle chains are merchandise of immunoglobulin synthesis and launched into the circulation in minor amounts corresponding to serum, cerebrospinal fluid, urine and synovial fluid in regular situation. The aim of this examine was the manufacturing and purification of polyclonal immunoglobulin G (IgG) in opposition to human kappa gentle chains.

On this examine, early human IgG was purified by ion-exchange chromatography, diminished with Dithiothreitol and heavy and lightweight chains have been separated with size-exclusion chromatography. Afterward, affinity chromatography with protein L Sepharose at pH 2.00 was exhibited to be a dominant situation for the separation and purification of the kappa gentle chain of immunoglobulins from human serum. Finally, the rabbit was immunized by human kappa gentle chains.

The rabbit IgG was purified and labeled with horseradish peroxidase (HRP). Direct enzyme-linked immunosorbent assay was deliberate to find out the titer of HRP conjugated rabbit IgG in opposition to the human kappa gentle chain. The optimum titer of anti-kappa IgG was 1:16000. On the end result, purified polyclonal anti-kappa is great tool in biomedical and biochemical researches and diagnostic kits.

Leave a Reply

Your email address will not be published. Required fields are marked *